AYTU BIOPHARMA, INC
AYTU BIOPHARMA, INC (AYTU): 12 pipeline candidates · 1 upcoming catalyst · ~28 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
27.9 months
0% dilution
Lead: Approved
12 candidates
1 upcoming, next in ~2242d
N/A
A transparent, data-derived signal for AYTU BIOPHARMA, INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$23.3M
Cash
$26.7M
Quarterly Burn
$4.2M
Runway
27.9 mo
Revenue
$12.4M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| 3,4-Methylenedioxymethamphetamine | Phase 2 |
| aciphex | Approved |
| Adzenys XR-ODT | Phase 4 |
| AR101 | — |
| Belsomra | N/A |
| Cotempla XR-ODT | Approved |
| EXXUA | Approved |
| Karbinal ER | Approved |
| Methylphenidate | N/A |
| Poly-Vi-Flor | Approved |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
33
Total value held
$7.9M
| Holder | Shares | Value |
|---|---|---|
| arete wealth advisors, llc | 49,549 | $4.0M |
| vanguard capital management llc | 522,292 | $1.4M |
| diadema partners lp | 353,077 | $964K |
| two sigma investments, lp | 121,973 | $333K |
| renaissance technologies llc | 93,723 | $256K |
| geode capital management, llc | 92,636 | $253K |
| vanguard fiduciary trust co | 47,048 | $128K |
| dimensional fund advisors lp | 43,585 | $119K |
| citadel advisors llc | 36,841 | $101K |
| bellevue asset management, llc | 25,013 | $68K |
Showing top 10 of 33 institutional holders of AYTU BIOPHARMA, INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in AYTU BIOPHARMA, INC's pipeline?
AYTU BIOPHARMA, INC (AYTU) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AYTU BIOPHARMA, INC's lead drug candidate?
AYTU BIOPHARMA, INC's most advanced tracked candidate is 3,4-Methylenedioxymethamphetamine (Phase 2) for Chronic Neuropathic Pain.
What is AYTU BIOPHARMA, INC's next catalyst?
AYTU BIOPHARMA, INC's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ZOLPIMIST" — expected August 7, 2032.
What is AYTU BIOPHARMA, INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AYTU BIOPHARMA, INC has approximately 27.9 months of cash runway.
What is AYTU BIOPHARMA, INC's market capitalization?
AYTU BIOPHARMA, INC's market capitalization is approximately $23.3M.
Get the full picture on AYTU BIOPHARMA, INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.